# US 2010/0166778 A1 · Toll-Like Receptor 3 Antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166778 A1
- Document ID: US20100166778A1
- Status: Published application
- Kind: A1
- Application number: 12/609,675
- Filed: 2009-10-30
- Published: 2010-07-01
- Earliest claimed: 2008-10-31
- Assignees: Janssen Biotech, Inc.
- Inventors: Mark Cunningham; Yiqing Feng; Katharine Heeringa; Jinquan Luo; Robert Rauchenberger; Mark Rutz; Lani San Mateo; Robert Sarisky; Raymond Sweet; Fang Teng; Alexey Teplyakov; Sheng-Jiun Wu
- Web page: https://patentgrep.com/patent/US20100166778A1

## CPC

- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 39/39533: {against materials from animals}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 31/16: for influenza or rhinoviruses
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07H 21/04: with deoxyribosyl as saccharide radical
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C12N 15/117: Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A61K 2039/505: {comprising antibodies}
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 16/18: against material from animals or humans
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C12N 5/10: Cells modified by introduction of foreign genetic material
- C12N 5/12: Fused cells, e.g. hybridomas
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 2310/17: Immunomodulatory nucleic acids
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

## Claims

### Claim 1

An isolated antibody or fragment thereof, wherein the antibody binds at least one toll-like receptor 3 (TLR3) amino acid residue selected from the group consisting of residues K467, R488 and R489 of SEQ ID NO: 2.

### Claim 2 (depends on 1)

The isolated antibody or fragment of claim 1, wherein the TLR3 amino acid residues are selected from the group consisting of:
a. residue K467 of SEQ ID NO: 2;
b. residue R489 of SEQ ID NO: 2;
c. residues K467 and R489 of SEQ ID NO: 2; and
d. residues K467, R488, and R489 of SEQ ID NO: 2.

### Claim 3 (depends on 1)

The isolated antibody or fragment of claim 1, wherein the antibody further binds at least one TLR3 amino acid residue selected from the group consisting of residues Y465, Y468, N517, D536, Q538, H539, N541, E570 and K619 of SEQ ID NO:2.

### Claim 4

An isolated antibody or fragment thereof, wherein the antibody binds at least one TLR3 amino acid residue selected from the group consisting of residues D116 and K145 of SEQ ID NO: 2.

### Claim 5 (depends on 3)

The isolated antibody or fragment of claim 3, wherein the TLR3 amino acid residues are selected from the group consisting of:
a. residue D116 of SEQ ID NO: 2; and
b. residues D116 and K145 of SEQ ID NO: 2.

### Claim 6

An isolated antibody or fragment reactive with TLR3, wherein the antibody has at least one of the following properties:
a. reduces human TLR3 biological activity in an in vitro poly(I:C) NF-κB reporter gene assay >50% at <1 μg/ml;
b. inhibits >60% of IL-6 or CXCL10/IP-10 production from BEAS-2B cells stimulated with <100 ng/ml poly(I:C) at <10 μg/ml;
c. inhibits >50% of IL-6 or CXCL10/IP-10 production from BEAS-2B cells stimulated with <100 ng/ml poly(I:C) at <0.4 μg/ml;
d. inhibits >50% of IL-6 production from NHBE cells stimulated with 62.5 ng/ml poly(I:C) at <5 μg/ml;
e. inhibits >50% of IL-6 production from NHBE cells stimulated with 62.5 ng/ml poly(I:C) at <1 μg/ml;
f. inhibits >20% of poly(I:C)-induced IFN-γ, IL-6 or IL-12 production by PBMC at <1 μg/ml;
g. inhibits cynomologus TLR3 biological activity in an in vitro NF-kB reporter gene assay with IC50<10 μg/ml; or
h. inhibits cynomologus TLR3 biological activity in an in vitro ISRE reporter gene assay with IC50<5 μg/ml.

### Claim 7

An isolated antibody or fragment reactive with TLR3 that competes for TLR3 binding with a monoclonal antibody comprising:
a. the heavy chain variable region of SEQ ID NO: 214; or
b. the light chain variable region of SEQ ID NO: 211; or
c. the heavy chain variable region of SEQ ID NO: 214 and the light chain variable region of SEQ ID NO: 211; or
d. the heavy chain complemetarity determining regions (CDR) 1, 2 and 3 (HCDR1, HCDR2 and HCDR3) amino acid sequences as shown in SEQ ID NO:s 70, 77 and 72; or
e. the light chain complemetarity determining regions (CDR) 1, 2 and 3 (LCDR1, LCDR2 and LCDR3) amino acid sequences as shown in SEQ ID NO:s 67, 68 and 78; or
f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 77 and 72 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 78; or
g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 214; or
h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 211.

### Claim 8

An isolated antibody or fragment reactive with TLR3 that competes for TLR3 binding with a monoclonal antibody comprising:
a. the heavy chain variable region of SEQ ID NO: 216; or
b. the light chain variable region of SEQ ID NO: 41; or
c. the heavy chain variable region of SEQ ID NO: 216 and the light chain variable region of SEQ ID NO: 41; or
d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 86 and 84; or
e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 87; or
f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 86 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 87; or
g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 216; or
h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 41.

### Claim 9

An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
a. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 61, 192 and 60, wherein the HCDR2 of SEQ ID NO: 192 is further defined as shown in Formula (I):
Xaa6-I-Xaa2-Xaa8-R-S-Xaa8-W-Y-N-D-Y-A-V-S-V-K-S, (I)
wherein
Xaa6 may be Arg or Lys;
Xaa2 may be Tyr, His or Ser;
Xaa8 may be Met, Arg or Tyr; and
Xaa8 may be Lys or Arg; or
b. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 191, wherein the LCDR3 of SEQ ID NO: 191 is further defined as shown in Formula (II):
Xaa1-S-Y-D-Xaa2-Xaa2-Xaa4-Xaa5-T-V, (II)
wherein
Xaa1 may be Ala, Gln, Gly or Ser;
Xaa2 may be Gly, Glu or Ser;
Xaa3 may be Asp or Asn;
Xaa4 may be Glu or Ser; and
Xaa5 may be Phe, Ala or Leu; or
c. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 61, 192 and 60, wherein the HCDR2 of SEQ ID NO: 192 is further defined as shown in Formula (I):
Xaa6-I-Xaa2-Xaa8-R-S-Xaa8-W-Y-N-D-Y-A-V-S-V-K-S, (I)
wherein
Xaa6 may be Arg or Lys;
Xaa7 may be Tyr, His or Ser;
Xaa8 may be Met, Arg or Tyr; and
Xaa8 may be Lys or Arg; and
the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 191, wherein the LCDR3 of SEQ ID NO: 191 is further defined as shown in Formula (II):
Xaa1-S-Y-D-Xaa2-Xaa8-Xaa4-Xaa5-T-V, (II)
wherein
Xaa1 may be Ala, Gln, Gly or Ser;
Xaa2 may be Gly, Glu or Ser;
Xaa8 may be Asp or Asn;
Xaa4 may be Glu or Ser; and
Xaa5 may be Phe, Ala or Leu; or
d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 194 and 72, wherein the HCDR2 of SEQ ID NO: 194 is further defined as shown in Formula (III):
I-I-Q-Xaa15-R-S-K-W—Y-N-Xaa16-Y-A-Xaa17-S-V-K-S, (III)
wherein
Xaam may be Lys, Thr or Ile;
Xaam may be Asn or Asp; and
Xaa17 may be Val or Leu; or
e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 193, wherein the LCDR3 of SEQ ID NO: 193 is further defined as shown in Formula (IV):
Xaa10-S-Y-D-Xaa11-P-Xaa12-Xaa13-Xaa14-V, (IV)
Wherein
Xaa10 may be Gln or Ser;
Xaa11 may be Thr, Glu or Asp;
Xaa12 may be Val or Asn;
Xaa13 may be Tyr or Phe; and
Xaa14 may be Ser, Asn or Gln; or
f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 194 and 72, wherein the HCDR2 of SEQ ID NO: 194 is further defined as shown in Formula (III):
I-I-Q-Xaa15-R-S-K-W—Y-N-Xaa16-Y-A-Xaa17-S-V-K-S, (III)
wherein
Xaa15 may be Lys, Thr or Ile;
Xaa16 may be Asn or Asp; and
Xaa17 may be Val or Leu; and
the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 193, wherein the LCDR3 of SEQ ID NO: 193 is further defined as shown in Formula (IV):
Xaa10-S-Y-D-Xaa11-P-Xaa12-Xaa13-Xaa14-V, (IV)
Wherein
Xaa10 may be Gln or Ser;
Xaa11 may be Thr, Glu or Asp;
Xaa12 may be Val or Asn;
Xaa13 may be Tyr or Phe; and
Xaa14 may be Ser, Asn or Gln.
g. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 196 and 84, wherein the HCDR2 of SEQ ID NO: 196 is further defined as shown in Formula (V):
Xaa24-I-D-P-S-D-S-Y-T-N-Y-Xaa25-P-S-F-Q-G, (V)
wherein
Xaa24 may be Phe or Arg; and
Xaa25 may be Ala or Ser; or
h. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 195, wherein the LCDR3 of SEQ ID NO: 195 is further defined as shown in Formula (VI):
Q-Q-Xaa18-Xaa19-Xaa20-Xaa21-Xaa22-Xaa23-T, (VI)
wherein
Xaa18 may be Tyr, Gly or Ala;
Xaa19 may be Gly, Glu or Asn;
Xaa20 may be Ser or Thr;
Xaa21 may be Val, Ile or Leu;
Xaa22 may be Ser or Leu; and
Xaa23 may be Ile, Ser, Pro or Tyr; or
i. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 196 and 84, wherein the HCDR2 of SEQ ID NO: 196 is further defined as shown in Formula (V):
Xaa24-I-D-P-S-D-S-Y-T-N-Y-Xaa25-P-S-F-Q-G, (V)
wherein
Xaa24 may be Phe or Arg; and
Xaa25 may be Ala or Ser; and
j. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 195, wherein the LCDR3 of SEQ ID NO: 195 is further defined as shown in Formula (VI):
Q-Q-Xaa18Xaa19-Xaa20-Xaa21-Xaa22-Xaa23-T, (VI)
wherein
Xaa18 may be Tyr, Gly or Ala;
Xaa19 may be Gly, Glu or Asn;
Xaa20 may be Ser or Thr;
Xaa21 may be Val, Ile or Leu;
Xaa22 may be Ser or Leu; and
Xaa23 may be Ile, Ser, Pro or Tyr.

### Claim 10

An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
a. the heavy chain variable region of SEQ ID NO: 6; or
b. the light chain variable region of SEQ ID NO: 5; or
c. the heavy chain variable region of SEQ ID NO: 6 and the light chain variable region of SEQ ID NO: 5; or
d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 52, 88 and 54; or
e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 49, 50 and 51; or
f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 52, 88 and 54; and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 49, 50 and 51; or
g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 7; or
h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 6.

### Claim 11

An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
a. the heavy chain variable region of SEQ ID NO: 8; or
b. the light chain variable region of SEQ ID NO: 7; or
c. the heavy chain variable region of SEQ ID NO: 8 and the light chain variable region of SEQ ID NO: 7; or
d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 58, 64 and 60; or
e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 57; or
f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 58, 64 and 60 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 57; or
g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 8; or
h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 7.

### Claim 12

An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
a. the heavy chain variable region of SEQ ID NO: 10; or
b. the light chain variable region of SEQ ID NO: 9; or
c. the heavy chain variable region of SEQ ID NO: 10 and the light chain variable region of SEQ ID NO: 9; or
d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 77 and 72; or
e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 69; or
f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 77 and 72 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 69; or
g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 10; or
h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 9.

### Claim 13

An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
a. the heavy chain variable region of SEQ ID NO: 12; or
b. the light chain variable region of SEQ ID NO: 11; or
c. the heavy chain variable region of SEQ ID NO: 12 and the light chain variable region of SEQ ID NO: 11; or
d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 83 and 84; or
e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 89; or
f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 83 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 89; or
g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 12; or
h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 11.

### Claim 14

An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
a. the heavy chain variable region of SEQ ID NO: 14; or
b. the light chain variable region of SEQ ID NO: 13; or
c. the heavy chain variable region of SEQ ID NO: 14 and the light chain variable region of SEQ ID NO: 13; or
d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 46, 47 and 48; or
e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 43, 44 and 45; or
f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 46, 47 and 48 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 43, 44 and 45; or
g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 14; or
h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 13.

### Claim 15

An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
a. the heavy chain variable region of SEQ ID NO: 16; or
b. the light chain variable region of SEQ ID NO: 15; or
c. the heavy chain variable region of SEQ ID NO: 16 and the light chain variable region of SEQ ID NO: 15; or
d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 52, 53 and 54; or
e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 49, 50 and 51; or
f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 52, 53 and 54 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 49, 50 and 51; or
g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 16; or
h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 15.

### Claim 16

An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
a. the heavy chain variable region of SEQ ID NO: 18; or
b. the light chain variable region of SEQ ID NO: 17; or
c. the heavy chain variable region of SEQ ID NO: 18 and the light chain variable region of SEQ ID NO: 17; or
d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 58, 59 and 60; or
e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 57; or
f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 58, 59 and 60 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 57; or
g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 18; or
h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 17.

### Claim 17

An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
a. the heavy chain variable region of SEQ ID NO: 20; or
b. the light chain variable region of SEQ ID NO: 19; or
c. the heavy chain variable region of SEQ ID NO: 20 and the light chain variable region of SEQ ID NO: 19; or
d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 61, 62 and 60; or
e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 57; or
f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 61, 62 and 60 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 57; or
g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 20; or
h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 19.

### Claim 18

An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
a. the heavy chain variable region of SEQ ID NO: 22; or
b. the light chain variable region of SEQ ID NO: 21; or
c. the heavy chain variable region of SEQ ID NO: 22 and the light chain variable region of SEQ ID NO: 21; or
d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 61, 64 and 60; or
e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 63; or
f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 61, 64 and 60 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 63; or
g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 22; or
h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 21.

### Claim 19

An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
a. the heavy chain variable region of SEQ ID NO: 24; or
b. the light chain variable region of SEQ ID NO: 23; or
c. the heavy chain variable region of SEQ ID NO: 24 and the light chain variable region of SEQ ID NO: 23; or
d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s s 61, 64 and 60; or
e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 65; or
f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 61, 64 and 60 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 65; or
g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 24; or
h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 23.

### Claim 20

An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
a. the heavy chain variable region of SEQ ID NO: 26; or
b. the light chain variable region of SEQ ID NO: 25; or
c. the heavy chain variable region of SEQ ID NO: 26 and the light chain variable region of SEQ ID NO: 25; or
d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 61, 64 and 60; or
e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 66; or
f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 61, 64 and 60 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 66; or
g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 26; or
h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 25.

### Claim 21

An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
a. the heavy chain variable region of SEQ ID NO: 28; or
b. the light chain variable region of SEQ ID NO: 27; or
c. the heavy chain variable region of SEQ ID NO: 28 and the light chain variable region of SEQ ID NO: 27; or
d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 71 and 72; or
e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 69; or
f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 71 and 72 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 69; or
g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 28; or
h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 27.

### Claim 22

An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
a. the heavy chain variable region of SEQ ID NO: 30; or
b. the light chain variable region of SEQ ID NO: 29; or
c. the heavy chain variable region of SEQ ID NO: 30 and the light chain variable region of SEQ ID NO: 29; or
d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 73 and 72; or
e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 69; or
f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 73 and 72 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 69; or
g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 30; or
h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 29.

### Claim 23

An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
a. the heavy chain variable region of SEQ ID NO: 32; or
b. the light chain variable region of SEQ ID NO: 31; or
c. the heavy chain variable region of SEQ ID NO: 32 and the light chain variable region of SEQ ID NO: 31; or
d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 75 and 72; or
e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 74; or
f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 75 and 72 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 74; or
g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 32; or
h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 31.

### Claim 24

An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
a. the heavy chain variable region of SEQ ID NO: 34; or
b. the light chain variable region of SEQ ID NO: 33; or
c. the heavy chain variable region of SEQ ID NO: 34 and the light chain variable region of SEQ ID NO: 33; or
d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 77 and 72; or
e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 76; or
f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 77 and 72 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 76; or
g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 34; or
h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 33.

### Claim 25

An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
a. the heavy chain variable region of SEQ ID NO: 36; or
b. the light chain variable region of SEQ ID NO: 35; or
c. the heavy chain variable region of SEQ ID NO: 36 and the light chain variable region of SEQ ID NO: 35; or
d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 77 and 72; or
e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 78; or
f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 77 and 72 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 78; or
g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 36; or
h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 35.

### Claim 26

An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
a. the heavy chain variable region of SEQ ID NO: 38; or
b. the light chain variable region of SEQ ID NO: 37; or
c. the heavy chain variable region of SEQ ID NO: 38 and the light chain variable region of SEQ ID NO: 37; or
d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 83 and 84; or
e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 81; or
f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 83 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 81; or
g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 38; or
h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 37.

### Claim 27

An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
a. the heavy chain variable region of SEQ ID NO: 40; or
b. the light chain variable region of SEQ ID NO: 39; or
c. the heavy chain variable region of SEQ ID NO: 40 and the light chain variable region of SEQ ID NO: 39; or
d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 86 and 84; or
e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 85; or
f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 86 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 85; or
g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 40; or
h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 39;
i. the heavy chain of SEQ ID NO: 102; or
j. the light chain of SEQ ID NO: 155; or
k. the heavy chain of SEQ ID NO: 102 and the light chain of SEQ ID NO: 155.

### Claim 28

An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
a. the heavy chain variable region of SEQ ID NO: 42; or
b. the light chain variable region of SEQ ID NO: 41; or
c. the heavy chain variable region of SEQ ID NO: 42 and the light chain variable region of SEQ ID NO: 41; or
d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 86 and 84; or
e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 87; or
f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 86 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 87; or
g. the heavy chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 42; or
h. the light chain variable region which is at least 95% identical to the variable region having an amino acid sequence of SEQ ID NO: 41;
i. the heavy chain of SEQ ID NO: 102; or
j. the light chain of SEQ ID NO: 156; or
k. the heavy chain of SEQ ID NO: 102 and the light chain of SEQ ID NO: 156.

### Claim 29

An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
a. the heavy chain variable region of SEQ ID NO: 216; or
b. the light chain variable region of SEQ ID NO: 41; or
c. the heavy chain variable region of SEQ ID NO: 216 and the light chain variable region of SEQ ID NO: 41; or
d. the heavy chain of SEQ ID NO: 220; or
e. the light chain of SEQ ID NO: 156; or
f. the heavy chain of SEQ ID NO: 220 and the light chain of SEQ ID NO: 156.

### Claim 30

An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
a. the heavy chain variable region of SEQ ID NO: 124; or
b. the heavy chain variable region of SEQ ID NO: 125; or
c. the heavy chain variable region of SEQ ID NO: 126; or
d. the heavy chain variable region of SEQ ID NO: 127; or
e. the heavy chain variable region of SEQ ID NO: 128; or
f. the heavy chain variable region of SEQ ID NO: 129; or
g. the heavy chain variable region of SEQ ID NO: 124 and the light chain variable region of SEQ ID NO: 41; or
h. the heavy chain variable region of SEQ ID NO: 125 and the light chain variable region of SEQ ID NO: 41; or
i. the heavy chain variable region of SEQ ID NO: 126 and the light chain variable region of SEQ ID NO: 41; or
j. the heavy chain variable region of SEQ ID NO: 127 and the light chain variable region of SEQ ID NO: 41; or
k. the heavy chain variable region of SEQ ID NO: 128 and the light chain variable region of SEQ ID NO: 41; or
the heavy chain variable region of SEQ ID NO: 129 and the light chain variable region of SEQ ID NO: 41; or
m. the light chain variable region of SEQ ID NO: 122; or
n. the light chain variable region of SEQ ID NO: 123; or
o. the heavy chain variable region of SEQ ID NO: 42 and the light chain variable region of SEQ ID NO: 122; or
p. the heavy chain variable region of SEQ ID NO: 42 and the light chain variable region of SEQ ID NO: 123; or
q. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 111, 112 and 84; or
r. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 111, 114 and 84; or
s. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 115, 112 and 84; or
t. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 116, 112 and 84; or
u. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 111, 117 and 84; or
v. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 116, 118 and 84; or
w. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 116, 112 and 119; or
x. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 116, 118 and 119; or
y. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 111, 112 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 109, 110 and 113; or
z. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 111, 114 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 109, 110 and 113; or
aa. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 115, 112 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 109, 110 and 113; or
bb. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 116, 112 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 109, 110 and 113; or
cc. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 111, 117 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 109, 110 and 113; or
dd. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 116, 118 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 109, 110 and 113; or
ee. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 116, 112 and 119 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 109, 110 and 113; or
ff. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 120, 110 and 113; or
gg. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 121, 110 and 113; or
hh. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 111, 112 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 120, 110 and 113; or
ii. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 111, 112 and 84 and the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 121, 110 and 113; or
jj. the heavy chain of SEQ ID NO: 130; or
kk. the heavy chain of SEQ ID NO: 131; or
ll. the heavy chain of SEQ ID NO: 132; or
mm. the heavy chain of SEQ ID NO: 133; or
nn. the heavy chain of SEQ ID NO: 134; or
oo. the heavy chain of SEQ ID NO: 135; or
pp. the heavy chain of SEQ ID NO: 160; or
qq. the heavy chain of SEQ ID NO: 130 and the light chain of SEQ ID NO: 156; or
rr. the heavy chain of SEQ ID NO: 131 and the light chain of SEQ ID NO: 156; or
ss. the heavy chain of SEQ ID NO: 132 and the light chain of SEQ ID NO: 156; or
tt. the heavy chain of SEQ ID NO: 133 and the light chain of SEQ ID NO: 156; or
uu. the heavy chain of SEQ ID NO: 134 and the light chain of SEQ ID NO: 156; or
vv. the heavy chain of SEQ ID NO: 135 and the light chain of SEQ ID NO: 156; or
ww. the heavy chain of SEQ ID NO: 160 and the light chain of SEQ ID NO: 156; or
xx. the light chain of SEQ ID NO: 157; or
yy. the light chain of SEQ ID NO: 158; or
zz. the heavy chain of SEQ ID NO: 102 and the light chain of SEQ ID NO: 157; or
aaa. the heavy chain of SEQ ID NO: 102 and the light chain of SEQ ID NO: 158.

### Claim 31 (depends on 7, 8)

The isolated antibody or fragment of claim 7 or 8, wherein the antibody is fully human.

### Claim 32 (depends on 7, 8)

The isolated antibody or fragment of claim 7 or 8, wherein the antibody or fragment is human-adapted.

### Claim 33 (depends on 7, 8)

The isolated antibody or fragment of claim 7 or 8, wherein the antibody is conjugated to polyethylene glycol.

### Claim 34 (depends on 7, 8)

The isolated antibody or fragment of claim 7 or 8 having an IgG4 isotype.

### Claim 35 (depends on 7, 8)

The isolated antibody or fragment of claim 7 or 8, wherein the Fc domain comprises S229P, P235A or L236A mutations.

### Claim 36 (depends on 7, 8)

A pharmaceutical composition comprising the isolated antibody or fragment of claim 7 or 8 and a pharmaceutically acceptable carrier.

### Claim 37

An isolated antibody or fragment reactive with TLR3 comprising both a heavy chain and a light chain variable region and wherein the antibody comprises:
a. the heavy chain variable region of SEQ ID NO: 164; or
b. the light chain variable region of SEQ ID NO: 163; pr
c. the heavy chain variable region of SEQ ID NO: 164 and
d. the light chain variable region of SEQ ID NO: 163; or
e. the heavy chain of SEQ ID NO: 166; or
f. the light chain of SEQ ID NO: 165; or
g. the heavy chain of SEQ ID NO: 166 and the light chain of SEQ ID NO: 165; or
h. the heavy chain of SEQ ID NO: 168; or
i. the light chain of SEQ ID NO: 167; or
j. the heavy chain of SEQ ID NO: 168 and the light chain of SEQ ID NO: 167.

### Claim 38

An isolated polynucleotide encoding an antibody heavy chain comprising the CDR amino acid sequences selected from the group consisting of:
a. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 61, 192 and 60, wherein the HCDR2 of SEQ ID NO: 192 is further defined as shown in Formula (I):
Xaa6-I-Xaa7-Xaa8-R-S-Xaa9-W-Y-N-D-Y-A-V-S-V-K-S
wherein
Xaa6 may be Arg or Lys;
Xaa7 may be Tyr, His or Ser;
Xaa8 may be Met, Arg or Tyr; and
Xaa8 may be Lys or Arg;
b. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 194 and 72, wherein the HCDR2 of SEQ ID NO: 194 is further defined as shown in Formula (III):
I-I-Q-Xaa15-R-S-K-W—Y-N-Xaa16-Y-A-Xaa17-S-V-K-S
wherein
Xaa15 may be Lys, Thr or Ile;
Xaa16 may be Asn or Asp; and
Xaa17 may be Val or Leu.
c. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 196 and 84, wherein the HCDR2 of SEQ ID NO: 196 is further defined as shown in Formula (V):
Xaa24-I-D-P-S-D-S-Y-T-N-Y-Xaa25-P-S-F-Q-G
wherein
Xaa24 may be Phe or Arg; and
Xaa25 may be Ala or Ser;
d. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 52, 88 and 54;
e. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 58, 64 and 60;
f. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s SEQ ID NOs: 70, 77 and 72;
g. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 83 and 84;
h. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 46, 47 and 48;
i. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 52, 53 and 54;
j. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 58, 59 and 60;
k. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 61, 62 and 60;
l. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 61, 64 and 60;
m. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 71 and 72;
n. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 73 and 72;
o. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 75 and 72;
p. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 70, 77 and 72;
q. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 83 and 84;
r. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 82, 86 and 84;
s. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 111, 114 and 84;
t. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 115, 112 and 84;
u. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 116, 112 and 84;
v. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 111, 117 and 84;
w. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 116, 118 and 84;
x. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 116, 112 and 119; and
y. the heavy chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 116, 118 and 119.

### Claim 39

An isolated polynucleotide encoding an antibody light chain comprising the CDR amino acid sequences selected from the group consisting of:
a. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 191, wherein the LCDR3 of SEQ ID NO: 191 is further defined as shown in Formula (II):
Xaa1-S-Y-D-Xaa2-Xaa2-Xaa4-Xaa5-T-V, (II)
wherein
Xaa1 may be Ala, Gln, Gly or Ser;
Xaa2 may be Gly, Glu or Ser;
Xaa3 may be Asp or Asn;
Xaa4 may be Glu or Ser; and
Xaa5 may be Phe, Ala or Leu; or
b. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 193, wherein the LCDR3 of SEQ ID NO: 193 is further defined as shown in Formula (IV):
Xaa10-S-Y-D-Xaa11-P-Xaa12-Xaa12-Xaa14-V, (IV)
Wherein
Xaa10 may be Gln or Ser;
Xaa11 may be Thr, Glu or Asp;
Xaa12 may be Val or Asn;
Xaa13 may be Tyr or Phe; and
Xaa14 may be Ser, Asn or Gln; or
c. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 195, wherein the LCDR3 of SEQ ID NO: 193 is further defined as shown in Formula (VI):
Q-Q-Xaa18-Xaa19-Xaa20-Xaa20-Xaa22-Xaa22T, (VI)
wherein
Xaa18 may be Tyr, Gly or Ala;
Xaa19 may be Gly, Glu or Asn;
Xaa20 may be Ser or Thr;
Xaa21 may be Val, Ile or Leu;
Xaa22 may be Ser or Leu; and
Xaa22 may be Ile, Ser, Pro or Tyr; or
d. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 49, 50 and 51;
e. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 57;
f. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 69;
g. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 89;
h. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 43, 44 and 45;
i. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 49, 50 and 51;
j. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 57;
k. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 63;
l. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 65;
m. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 55, 56 and 66;
n. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 69;
o. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 74;
p. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 76;
q. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 67, 68 and 78;
r. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 81;
s. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 85;
t. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 79, 80 and 87;
u. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 109, 110 and 113;
v. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 120, 110 and 113; and
w. the light chain CDR 1, 2 and 3 amino acid sequences as shown in SEQ ID NO:s 121, 110 and 113;

### Claim 40

An isolated polynucleotide encoding an antibody heavy chain comprising the amino acid sequence shown in SEQ ID NO: 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 124, 125, 126, 127, 128, 129, 159, 198, 200, 202, 164, 212, 213, 214, 215 or 216.

### Claim 41

An isolated polynucleotide encoding an antibody light chain comprising the amino acid sequence shown in SEQ ID NO: 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 122, 123, 197, 199, 201, 163, 209, 210 or 211.

### Claim 42

An isolated polynucleotide encoding an antibody heavy chain comprising the amino acid sequence shown in SEQ ID NO: 102, 130, 131, 132, 133, 134, 135, 160, 204, 206, 208, 220, 166 or 168.

### Claim 43

An isolated polynucleotide encoding an antibody light chain comprising the amino acid sequence shown in SEQ ID NO: 155, 156, 157, 158, 203, 205, 207, 165 or 167.

### Claim 44

An isolated antibody heavy chain comprising the amino acid sequence shown in SEQ ID NO: 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 124, 125, 126, 127, 128, 129, 159, 198, 200, 202, 164, 212, 213, 214, 215 or 216.

### Claim 45

An isolated antibody light chain comprising the amino acid sequence shown in SEQ ID NO: 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 122, 123, 197, 199, 201, 163, 209, 210 or 211.

### Claim 46

An isolated antibody heavy chain comprising the amino acid sequence shown in SEQ ID NO: 102, 130, 131, 132, 133, 134, 135, 160, 204, 206, 208, 220, 166 or 168.

### Claim 47

An isolated antibody light chain comprising the amino acid sequence shown in SEQ ID NO: 155, 156, 157, 158, 203, 205, 207, 165 or 167.

### Claim 48 (depends on 7, 8)

A method of treating an inflammatory condition comprising administering a therapeutically effective amount of the isolated antibody of claim 7 or 8 to a patient in need thereof for a time sufficient to treat or prevent the inflammatory condition.

### Claim 49 (depends on 48)

The method of claim 48, wherein the inflammatory condition affects a tissue selected from a group consisting of the respiratory tract, lung, the gastrointestinal tract, small intestine, large intestine, colon, rectum, the cardiovascular system, cardiac tissue, blood vessels, joint, bone and synovial tissue, cartilage, epithelium, endothelium, hepatic or adipose tissue.

### Claim 50 (depends on 48)

The method of claim 48, wherein the inflammatory condition is associated with increased TLR3-mediated neutrophil infiltration into the tissue.

### Claim 51 (depends on 48)

The method of claim 48, wherein the inflammatory condition is an inflammatory pulmonary condition.

### Claim 52 (depends on 51)

The method of claim 51, wherein the inflammatory pulmonary condition is asthma or chronic obstructive pulmonary disease (COPD).

### Claim 53 (depends on 51)

The method of claim 51, wherein the inflammatory pulmonary condition is induced by Nontypeable Haemophilus influenza.

### Claim 54 (depends on 51)

The method of claim 51, wherein the inflammatory pulmonary condition is airway hyperresponsiveness.

### Claim 55 (depends on 54)

The method of claim 54, wherein the airway hyperresponsiveness is associated with asthma, allergic rhinitis, COPD, or cystic fibrosis.

### Claim 56 (depends on 48)

The method of claim 48, wherein the inflammatory condition is an inflammatory bowel disease.

### Claim 57 (depends on 48)

The method of claim 48, wherein the inflammatory condition is associated with gastrointestinal ulceration.

### Claim 58 (depends on 57)

The method of claim 57, wherein the gastrointestinal ulceration is associated with infectious colitis, ischemic colitis, collagenous or lymphocytic colitis or necrotizing enterocolitis.

### Claim 59 (depends on 48)

The method of claim 48, wherein the inflammatory condition is an autoimmune disease.

### Claim 60 (depends on 59)

The method of claim 59, wherein the autoimmune disease is rheumatoid arthritis.

### Claim 61 (depends on 7, 8)

A method of treating or preventing a systemic inflammatory condition comprising administering a therapeutically effective amount of the isolated antibody of claim 7 or 8 to a patient in need thereof for a time sufficient to treat or prevent the systemic inflammatory condition.

### Claim 62 (depends on 61)

The method of claim 61, wherein the systemic inflammatory condition is cytokine storm or hypercytokinemia, systemic inflammatory response syndrome (SIRS), graft versus host disease (GVHD), acute respiratory distress syndrome (ARDS), severe acute respiratory distress syndrome (SARS), catastrophic anti-phospholipid syndrome, severe viral infections, influenza, pneumonia, shock, or sepsis.

### Claim 63 (depends on 7, 8)

A method of treating type II diabetes comprising administering a therapeutically effective amount of the isolated antibody of claim 7 or 8 to a patient in need thereof for a time sufficient to treat type II diabetes.

### Claim 64 (depends on 7, 8)

A method of treating hyperglycemia comprising administering a therapeutically effective amount of the isolated antibody of claim 7 or 8 to a patient in need thereof for a time sufficient to treat the hyperglycemia.

### Claim 65 (depends on 7, 8)

A method of treating hyperinsulinemia comprising administering a therapeutically effective amount of the isolated antibody of claim 7 or 8 to a patient in need thereof for a time sufficient to treat the insulin resistance.

### Claim 66 (depends on 7, 8)

A method of treating or preventing viral infections comprising administering a therapeutically effective amount of the isolated antibody of claim 7 or 8 to a patient in need thereof for a time sufficient to treat or prevent viral infections.

### Claim 67 (depends on 66)

A method of claim 66, wherein the viral infection is influenza A virus infection.
